Host-virus interactions in hepatitis B virus infection

Current Opinion in Immunology

Volumn 36, Issue , 2015, Pages 61-66

  Guidotti, Luca G ^a   Isogawa, Masanori ^b   Chisari, Francis V ^c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HEPATITIS B VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; CANCER SUSCEPTIBILITY; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CHRONIC HEPATITIS B; DISEASE COURSE; DISEASE SEVERITY; HEPATITIS B VIRUS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INNATE IMMUNITY; LIVER CELL CARCINOMA; LIVER NECROSIS; LYMPHOCYTE FUNCTION; NONHUMAN; PERSISTENT VIRUS INFECTION; REVIEW; VACCINATION; VIRUS CELL INTERACTION; ANIMAL; HEPATITIS B; HOST PATHOGEN INTERACTION; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION; VIROLOGY;

ADAPTIVE IMMUNITY; ANIMALS; HEPATITIS B; HEPATITIS B VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; IMMUNOMODULATION; T-LYMPHOCYTE SUBSETS;

EID: 84937012940     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.06.016     Document Type: Review

References (57)

1. Seeger C., Mason W.S. Molecular biology of hepatitis B virus infection. Virology 2015, 479-480C:672-686.
2. Wieland S., Thimme R., Purcell R.H., Chisari F.V. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004, 101:6669-6674.
3. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995, 13:29-60.
4. Guidotti L.G., Chisari F.V. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006, 1:23-61.
5. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4:25-36.
6. Ciupe S.M., Ribeiro R.M., Perelson A.S. Antibody responses during hepatitis B viral infection. PLoS Comput Biol 2014, 10:e1003730.
7. Di Bisceglie A.M. Hepatitis B and hepatocellular carcinoma. Hepatology 2009, 49:S56-S60.
8. Wasley A., Kruszon-Moran D., Kuhnert W., Simard E.P., Finelli L., McQuillan G., Bell B. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010, 202:192-201.
9. Burns G.S., Thompson A.J. Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med 2014, 4:a024935.
10. Zoulim F., Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med 2015, 5.
11. Boni C., Laccabue D., Lampertico P., Giuberti T., Vigano M., Schivazappa S., Alfieri A., Pesci M., Gaeta G.B., Brancaccio G., et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012, 143. 963-973 e969.
12. Ferrari C. HBV and the immune response. Liver Int 2015, 35(Suppl. 1):121-128.
13. Thimme R., Wieland S., Steiger C., Ghrayeb J., Reimann K.A., Purcell R.H., Chisari F.V. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003, 77:68-76.
14. Sato S., Li K., Kameyama T., Hayashi T., Ishida Y., Murakami S., Watanabe T., Iijima S., Sakurai Y., Watashi K., et al. The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 2015, 42:123-132.
15. Baron J.L., Gardiner L., Nishimura S., Shinkai K., Locksley R., Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002, 16:583-594.
16. Vilarinho S., Ogasawara K., Nishimura S., Lanier L.L., Baron J.L. Blockade of NKG2D on NKT cells prevents hepatitis and the acute immune response to hepatitis B virus. Proc Natl Acad Sci U S A 2007, 104:18187-18192.
17. Zeissig S., Murata K., Sweet L., Publicover J., Hu Z., Kaser A., Bosse E., Iqbal J., Hussain M.M., Balschun K., et al. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat Med 2012, 18:1060-1068.
18. Guidotti L.G., Morris A., Mendez H., Koch R., Silverman R.H., Williams B.R., Chisari F.V. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol 2002, 76:2617-2621.
19. McClary H., Koch R., Chisari F.V., Guidotti L.G. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000, 74:2255-2264.
20. Wieland S.F., Guidotti L.G., Chisari F.V. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000, 74:4165-4173.
21. Robek M.D., Boyd B.S., Chisari F.V. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005, 79:3851-3854.
22. Kakimi K., Guidotti L.G., Koezuka Y., Chisari F.V. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000, 192:921-930.
23. Kimura K., Kakimi K., Wieland S., Guidotti L.G., Chisari F.V. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. J Immunol 2002, 169:5188-5195.
24. Isogawa M., Robek M.D., Furuichi Y., Chisari F.V. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005, 79:7269-7272.
25. Lanford R.E., Guerra B., Chavez D., Giavedoni L., Hodara V.L., Brasky K.M., Fosdick A., Frey C.R., Zheng J., Wolfgang G., et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013, 144:1508-1517. 1517, e1501-1510.
26. Purcell R.H., London W.T., McAuliffe V.J., Palmer A.E., Kaplan P.M., Gerin J.L., Wagner J., Popper H., Lvovsky E., Wong D.C., et al. Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer. Lancet 1976, 2:757-761.
27. Gao B., Radaeva S., Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 2009, 86:513-528.
28. Tang X.Z., Jo J., Tan A.T., Sandalova E., Chia A., Tan K.C., Lee K.H., Gehring A.J., De Libero G., Bertoletti A. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol 2013, 190:3142-3152.
29. Jo J., Tan A.T., Ussher J.E., Sandalova E., Tang X.Z., Tan-Garcia A., To N., Hong M., Chia A., Gill U.S., et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog 2014, 10:e1004210.
30. Schurich A., Pallett L.J., Lubowiecki M., Singh H.D., Gill U.S., Kennedy P.T., Nastouli E., Tanwar S., Rosenberg W., Maini M.K. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog 2013, 9:e1003208.
31. Dunn C., Brunetto M., Reynolds G., Christophides T., Kennedy P.T., Lampertico P., Das A., Lopes A.R., Borrow P., Williams K., et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007, 204:667-680.
32. Peppa D., Gill U.S., Reynolds G., Easom N.J., Pallett L.J., Schurich A., Micco L., Nebbia G., Singh H.D., Adams D.H., et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 2013, 210:99-114.
33. Huang L.R., Wohlleber D., Reisinger F., Jenne C.N., Cheng R.L., Abdullah Z., Schildberg F.A., Odenthal M., Dienes H.P., van Rooijen N., et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol 2013, 14:574-583.
34. Chen M., Sallberg M., Hughes J., Jones J., Guidotti L.G., Chisari F.V., Billaud J.N., Milich D.R. Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 2005, 79:3016-3027.
35. Chen M.T., Billaud J.N., Sallberg M., Guidotti L.G., Chisari F.V., Jones J., Hughes J., Milich D.R. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A 2004, 101:14913-14918.
36. Reignat S., Webster G.J., Brown D., Ogg G.S., King A., Seneviratne S.L., Dusheiko G., Williams R., Maini M.K., Bertoletti A. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 2002, 195:1089-1101.
37. Bertoletti A., Sette A., Chisari F.V., Penna A., Levrero M., De Carli M., Fiaccadori F., Ferrari C. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994, 369:407-410.
38. Rehermann B., Pasquinelli C., Mosier S.M., Chisari F.V. Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest 1995, 96:1527-1534.
39. Isogawa M., Chung J., Murata Y., Kakimi K., Chisari F.V. CD40 activation rescues antiviral CD8(+) T cells from PD-1-mediated exhaustion. PLoS Pathog 2013, 9:e1003490.
40. Publicover J., Gaggar A., Nishimura S., Van Horn C.M., Goodsell A., Muench M.O., Reinhardt R.L., van Rooijen N., Wakil A.E., Peters M., et al. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J Clin Invest 2013, 123:3728-3739.
41. Bottcher J.P., Schanz O., Wohlleber D., Abdullah Z., Debey-Pascher S., Staratschek-Jox A., Hochst B., Hegenbarth S., Grell J., Limmer A., et al. Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity. Cell Rep 2013, 3:779-795.
42. Schurich A., Khanna P., Lopes A.R., Han K.J., Peppa D., Micco L., Nebbia G., Kennedy P.T., Geretti A.M., Dusheiko G., et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011, 53:1494-1503.
43. Nebbia G., Peppa D., Schurich A., Khanna P., Singh H.D., Cheng Y., Rosenberg W., Dusheiko G., Gilson R., ChinAleong J., et al. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One 2012, 7:e47648.
44. Billerbeck E., Bottler T., Thimme R. Regulatory T cells in viral hepatitis. World J Gastroenterol 2007, 13:4858-4864.
45. Pallett L.J., Gill U.S., Quaglia A., Sinclair L.V., Jover-Cobos M., Schurich A., Singh K.P., Thomas N., Das A., Chen A., et al. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat Med 2015, 21:591-600.
46. Das A., Ellis G., Pallant C., Lopes A.R., Khanna P., Peppa D., Chen A., Blair P., Dusheiko G., Gill U., et al. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol 2012, 189:3925-3935.
47. Guidotti L.G., Inverso D., Sironi L., Di Lucia P., Fioravanti J., Ganzer L., Fiocchi A., Vacca M., Aiolfi R., Sammicheli S., et al. Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell 2015, 161:486-500.
48. Vollmar B., Menger M.D. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev 2009, 89:1269-1339.
49. Krebs K., Bottinger N., Huang L.R., Chmielewski M., Arzberger S., Gasteiger G., Jager C., Schmitt E., Bohne F., Aichler M., et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 2013, 145:456-465.
50. Gehring A.J., Xue S.A., Ho Z.Z., Teoh D., Ruedl C., Chia A., Koh S., Lim S.G., Maini M.K., Stauss H., et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 2011, 55:103-110.
51. Qasim W., Brunetto M., Gehring A.J., Xue S.A., Schurich A., Khakpoor A., Zhan H., Ciccorossi P., Gilmour K., Cavallone D., et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015, 62:486-491.
52. Nakamoto Y., Guidotti L.G., Kuhlen C.V., Fowler P., Chisari F.V. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998, 188:341-350.
53. Nakamoto Y., Suda T., Momoi T., Kaneko S. Different procarcinogenic potentials of lymphocyte subsets in a transgenic mouse model of chronic hepatitis B. Cancer Res 2004, 64:3326-3333.
54. Iannacone M., Sitia G., Isogawa M., Marchese P., Castro M.G., Lowenstein P.R., Chisari F.V., Ruggeri Z.M., Guidotti L.G. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med 2005, 11:1167-1169.
55. Sitia G., Aiolfi R., Di Lucia P., Mainetti M., Fiocchi A., Mingozzi F., Esposito A., Ruggeri Z.M., Chisari F.V., Iannacone M., et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A 2012, 109:E2165-E2172.
56. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829.
57. Asabe S., Wieland S.F., Chattopadhyay P.K., Roederer M., Engle R.E., Purcell R.H., Chisari F.V. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009, 83:9652-9662.